www.public4you.fora.pl

syth33dsvdc

Intensive local hedge fund set up: Focus on China listed companies in the U.S.

group to focus on overseas China's small and medium capitalization stocks in the
our reporter was reporting from Shanghai Airlines

Introduction.
luck in the last days of 2009,Abercrombie, door - Dec. 28 morning, YIN Wei-dong office in Beijing's Zhongguancun, rush to look at more than 10 suits, sharp tone, guests, dense A packed house.

general manager of the Sinovac Biotech has always felt a lack of listener. Local funds in the first visit of China before Wall Street came to him all people.
investors, but those who spoke English so YIN Wei-dong racking tongue, but not to the Yin brings good luck. Wall Street in the collapse of the end of 2008, in New York-listed Sinovac Biotech (Nasdaq: SVA) test a low price to 0.4 U.S. dollars.
This means that by Sinovac missed a golden opportunity to re-finance expansion, so that when in 2009, YIN Wei-dong Sinovac led his team developed the world's first national pandemic influenza vaccine and won large orders , the limited capacity to make them unable to catch more wealth, while families with independent intellectual property rights Hing said the vaccine more than 80% gross margin.
story December 30, 2009, Sinovac Biotech in the U.S. price of $ 6.34.
but it seems about to change. Recently, a group focused on investing in overseas-listed Chinese stocks small market hedge funds in Shenzhen, Shanghai intensive set up, they said the pricing power to seize, to change those .
This may be as many as Sinovac is full of regret that the company turn for the better. These companies have 150 or so, when the A-share companies even pull Yang Xian, when one after another, they have endured across the Atlantic several times or even only ten times earnings, some companies share price fell $ 5 less, but also small enough volume poor.
the vaccine business of Wall Street pain

YIN Wei-dong for the first time this is the case in the absence of translation and investor communication.
2009 年 12 月 28 that day, from around the country about more than 10 private equity fund managers, similar to Sinovac Biotech launched research. YIN Wei-dong they have no obstacles to listen about his dream, and Sinovac future planning.
Sinovac these fund managers are very familiar situation, and put forward a number of recommendations,

YIN Wei-dong was never fun. Previously, when some U.S. investors across the oceans door, it will not always with the English translation of his effort to explain to them the kingdom of their own vaccines.

look indifferent to listening to each other, they went straight to a crucial opening - a lot of
awkward, not just Sinovac experienced.
? who has accompanied more than a dozen hedge funds to the overseas Chinese Internet companies describe the research, said hedge fund manager, especially when China's CEO is not English, then translated a lot of filtering, it is difficult to resonate with these funds.

addition to the few and generally unsuccessful face to face exchanges, foreign investors understand the channels of overseas-listed Chinese companies, on the left of each quarter conference call. In order to strengthen interaction with overseas investors, Sinovac roadshow to the United States each year 3-5. However, asymmetric information, cultural differences remain between the two sides erase barriers.
2003 when the SARS outbreak, YIN Wei-dong they stopped all the items on hand, to put SARS vaccine research and development, and at their own expense to complete a clinical certification. But with the SARS outbreak quickly ended once again Sinovac slump, which almost fell in a financial crisis. Finally, in order to reverse the acquisition of the form of Sinovac OTCBB markets to the United States,Ralph Lauren pas cher, raised $ 10,000,000, before back to life.

avian flu outbreak, YIN Wei-dong that
not suitable for some Chinese stocks.
2009 年 9 on 3, a flow of Sinovac's vaccine production and the State Food and Drug Administration approved the license, as the world's first H1N1 vaccine manufacturers. Announcement date, Sinovac Biotech stock prices in the United States rushed to $ 10.3. Previously, from 2003 listed on OTCBB in the United States since the Sinovac Biotech stock price has remained at 2-3 dollars.
U.S. investors do not make good on this trend anticipation.
not really exist. The domestic bio-medicine and happens often seen as a liar in the industry.
New Wealth China concept stocks

popular even experiencing a situation, the contribution to weed out the performance of the vaccine, Sinovac Biotech current price-earnings ratio is still less than 20 times In the A-share listed companies of similar objects such as Westlands, the highest price-earnings ratio reached 80-100 times.
In his view, there is also the ninth city to be underestimated, widely advertised, Acorn, Noah, Linktone, a large number of American Dairy loud in the name of the first domestic enterprise. These enterprises in the United States, the stock price hovering at a very low long-term valuations.
So, with the A shares of the growing high overall price-earnings ratio, is the emergence of a focus on domestic investment in Hong Kong and China, the United States the concept of the market value of listed shares of small and medium sized private equity funds.
opportunities.
started in Hong Kong offices and accounts outside the U.S. through its accounts, freely traded in the U.S. listed Chinese stocks.
Most of these funds from the domestic public offering some well-known fund manager to resign from founder, has extensive investment experience. However, Fan Weiqiang view,abercrombie outlet, their natural advantage is asymmetric information, p> At present, this group of overseas Chinese stocks to focus on private equity funds,abercrombie, listed companies frequently to research, it is far from investors in the United States very difficult to achieve.
pricing power struggle based on cultural differences

With the growth of this group, which in some Chinese stocks, China began to appear around the valuation of private equity and the pricing power of U.S. agencies struggle .
Fund daunting,MBT Sito Ufficiale, so most of these Chinese are only very few private or simply not use derivative instruments, but
through intensive research, Fan Weiqiang and his colleagues are exploring with good growth in China has a very low valuation of stocks and long-term holding. Shigekura they enter, so that Sinovac Biotech continuous rise in the last few trading days.
the eyes in the Fan Weiqiang, in addition to a few companies such as Baidu investors still sought after by the United States, most small and medium capitalization stocks in China has reached or no down time - now, about the total number of such shares In the 100 or so.
A high share compared to earnings ratio, the risk is still much lower. In such a rational market, a concept rarely appears alone can dramatically lift the stock price situation. To institutional investors is value-based listed company's actual profitability and financial position.
Therefore, in Wall Street, stock prices below $ 5 less access to institutional small cap stock investment, trading volume of long-term decline.
In addition, financial instruments developed in the U.S. market, and no ups and downs restrictions tend to increase stock price volatility, which can lead to some small-cap stocks will fall an incredible price. China private equity fund that provides for some profit opportunities.
the company's pricing power will be in Chinese hands after all.